Compare Merck & Co., Inc. (MRK) vs Essential Utilities Inc. Common Stock (WTRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Essential Utilities Inc. Common Stock — how do they compare? Merck & Co., Inc. trades at $150.62 (market cap $350.29B), while Essential Utilities Inc. Common Stock trades at $39.82 (market cap $11.15B). The key difference: Merck & Co., Inc. is far larger — about 31.4× Essential Utilities Inc. Common Stock's market cap, and Essential Utilities Inc. Common Stock pays the higher dividend (3.67%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Essential Utilities Inc. Common Stock for 0 Days on average.
| MRK | WTRG | |
|---|---|---|
Market Cap | $350.29B | $11.15B |
Volume | 8,158,912 | 1,760,234 |
Sector | Health | Utilities |
52-Week High | $156.43 | $42.00 |
52-Week Low | $82.49 | $36.25 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $19.66B |
Dividend Yield | 2.39% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.
The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.
WTRG trades at $39.29, up 0.36% with neutral technical signals. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining strong profitability margins (21.6% net income margin). Analyst consensus is bullish with a $44.50 price target, supported by ongoing acquisitions and pending merger developments with American Water.
The stock presents a stable utility investment with moderate growth potential through strategic acquisitions, though near-term earnings volatility and integration risks from the pending merger warrant caution. Current valuation at 20.15 P/E appears reasonable given the company's consistent cash flow generation and defensive sector positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Essential Utilities Inc. Common Stock
Essential Utilities Inc. is a holding company for regulated water, wastewater, and natural gas utilities, operating under the Aqua and Peoples brands. It serves customers across Pennsylvania, Ohio, Texas, Illinois, North Carolina, New Jersey, Indiana, Virginia, and Kentucky.
Read more on WTRG →
